MPH HEALTH CARE AG KONV (93M1.DE) Stock Fundamental Analysis
Europe - FRA:93M1 - DE000A289V03 - Common Stock
17.95 EUR
-0.35 (-1.91%)
Taking everything into account, 93M1 scores 2 out of 10 in our fundamental rating. 93M1 was compared to 53 industry peers in the Pharmaceuticals industry. 93M1 scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. 93M1 is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
93M1 had negative earnings in the past year.
In the past year 93M1 had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: 93M1 reported negative net income in multiple years.
In multiple years 93M1 reported negative operating cash flow during the last 5 years.
1.2 Ratios
93M1 has a Return On Assets of -52.66%. This is amonst the worse of the industry: 93M1 underperforms 81.13% of its industry peers.
93M1's Return On Equity of -56.18% is on the low side compared to the rest of the industry. 93M1 is outperformed by 77.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -52.66% | ||
| ROE | -56.18% | ||
| ROIC | N/A |
ROA(3y)11.46%
ROA(5y)-0.71%
ROE(3y)12.15%
ROE(5y)-0.63%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
93M1's Profit Margin has improved in the last couple of years.
93M1 does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y32.91%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
93M1 does not have a ROIC to compare to the WACC, probably because it is not profitable.
93M1 has about the same amout of shares outstanding than it did 1 year ago.
93M1 has about the same amout of shares outstanding than it did 5 years ago.
Compared to 1 year ago, 93M1 has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 4.60 indicates that 93M1 is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.60, 93M1 is in the better half of the industry, outperforming 69.81% of the companies in the same industry.
93M1 has a debt to FCF ratio of 5.58. This is a neutral value as 93M1 would need 5.58 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 5.58, 93M1 is in line with its industry, outperforming 43.40% of the companies in the same industry.
A Debt/Equity ratio of 0.02 indicates that 93M1 is not too dependend on debt financing.
The Debt to Equity ratio of 93M1 (0.02) is better than 88.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 5.58 | ||
| Altman-Z | 4.6 |
ROIC/WACCN/A
WACC7.05%
2.3 Liquidity
A Current Ratio of 0.40 indicates that 93M1 may have some problems paying its short term obligations.
93M1 has a Current ratio of 0.40. This is amonst the worse of the industry: 93M1 underperforms 90.57% of its industry peers.
A Quick Ratio of 0.40 indicates that 93M1 may have some problems paying its short term obligations.
93M1 has a Quick ratio of 0.40. This is amonst the worse of the industry: 93M1 underperforms 90.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.4 | ||
| Quick Ratio | 0.4 |
3. Growth
3.1 Past
The earnings per share for 93M1 have decreased strongly by -196.45% in the last year.
Measured over the past years, 93M1 shows a very strong growth in Earnings Per Share. The EPS has been growing by 23.67% on average per year.
Looking at the last year, 93M1 shows a very strong growth in Revenue. The Revenue has grown by 104.72%.
The Revenue has been decreasing by -6.95% on average over the past years.
EPS 1Y (TTM)-196.45%
EPS 3YN/A
EPS 5Y23.67%
EPS Q2Q%-197.62%
Revenue 1Y (TTM)104.72%
Revenue growth 3Y-4.71%
Revenue growth 5Y-6.95%
Sales Q2Q%166.92%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for 93M1. In the last year negative earnings were reported.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
93M1's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 36.6 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
93M1 has a Yearly Dividend Yield of 6.47%, which is a nice return.
93M1's Dividend Yield is rather good when compared to the industry average which is at 2.99. 93M1 pays more dividend than 96.23% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.39, 93M1 pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 6.47% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DP0%
EPS Next 2YN/A
EPS Next 3YN/A
FRA:93M1 (11/4/2025, 7:00:00 PM)
17.95
-0.35 (-1.91%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners0.96%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap76.83M
Revenue(TTM)52.00K
Net Income(TTM)-115232100
Analysts85.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 6.47% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1477.42 | ||
| P/FCF | 36.6 | ||
| P/OCF | 36.53 | ||
| P/B | 0.37 | ||
| P/tB | 0.37 | ||
| EV/EBITDA | N/A |
EPS(TTM)-26.91
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.49
FCFY2.73%
OCF(TTM)0.49
OCFY2.74%
SpS0.01
BVpS47.93
TBVpS47.93
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -52.66% | ||
| ROE | -56.18% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | 4036.73% |
ROA(3y)11.46%
ROA(5y)-0.71%
ROE(3y)12.15%
ROE(5y)-0.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y32.91%
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 5.58 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.4 | ||
| Quick Ratio | 0.4 | ||
| Altman-Z | 4.6 |
F-Score4
WACC7.05%
ROIC/WACCN/A
Cap/Depr(3y)20.66%
Cap/Depr(5y)19.86%
Cap/Sales(3y)15.7%
Cap/Sales(5y)12.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-196.45%
EPS 3YN/A
EPS 5Y23.67%
EPS Q2Q%-197.62%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)104.72%
Revenue growth 3Y-4.71%
Revenue growth 5Y-6.95%
Sales Q2Q%166.92%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-19.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y40.36%
FCF growth 3YN/A
FCF growth 5Y-24.11%
OCF growth 1Y40.11%
OCF growth 3YN/A
OCF growth 5Y-24.28%
MPH HEALTH CARE AG KONV / 93M1.DE FAQ
Can you provide the ChartMill fundamental rating for MPH HEALTH CARE AG KONV?
ChartMill assigns a fundamental rating of 2 / 10 to 93M1.DE.
What is the valuation status of MPH HEALTH CARE AG KONV (93M1.DE) stock?
ChartMill assigns a valuation rating of 1 / 10 to MPH HEALTH CARE AG KONV (93M1.DE). This can be considered as Overvalued.
Can you provide the profitability details for MPH HEALTH CARE AG KONV?
MPH HEALTH CARE AG KONV (93M1.DE) has a profitability rating of 1 / 10.
Can you provide the dividend sustainability for 93M1 stock?
The dividend rating of MPH HEALTH CARE AG KONV (93M1.DE) is 6 / 10 and the dividend payout ratio is 0%.